Lee's Pharmaceutical Holdings Limited released its earnings results on Aug 26, 2025. The company reported HK$0.114 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.114.

Is Lee's Pharmaceutical Holdings Limited overvalued?

According to Wall Street analysts Lee's Pharmaceutical Holdings Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Lee's Pharmaceutical Holdings Limited pay dividends?

Lee's Pharmaceutical Holdings Limited pays a Quarterly dividend of HK$0.022 which represents an annual dividend yield of 2.1%. See more information on Lee's Pharmaceutical Holdings Limited dividends here

What is Lee's Pharmaceutical Holdings Limited’s EPS estimate?

Lee's Pharmaceutical Holdings Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lee's Pharmaceutical Holdings Limited have?

Lee's Pharmaceutical Holdings Limited has 588,835,300 shares outstanding.

What happened to Lee's Pharmaceutical Holdings Limited’s price movement after its last earnings report?

Lee's Pharmaceutical Holdings Limited reported an EPS of HK$0.114 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1%.

Which hedge fund is a major shareholder of Lee's Pharmaceutical Holdings Limited?

Currently, no hedge funds are holding shares in HK:0950

Lee's Pharmaceutical Holdings Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

5.35%

Trailing 12-Months

Asset Growth

17.56%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Lee's Pharmaceutical Holdings Limited

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.